Shanghai Fudan Zhangjiang Bio Pharm : ANNOUNCEMENT ON RESUMPTION OF THE REVIEW PROCESS OF THE PROPOSED ISSUE OF A SHARES

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ANNOUNCEMENT ON RESUMPTION OF THE REVIEW PROCESS OF

THE PROPOSED ISSUE OF A SHARES

This announcement is made by Shanghai Fudan-ZhangjiangBio-Pharmaceutical Co., Ltd.* (the "Company") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the Company's announcement dated 31 July 2019, in relation to the application for suspension of the review process of the initial public issue of A shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the "Shanghai Stock Exchange") by the Company (the "Proposed Issue of A Shares"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the above announcement.

The Company has published the interim results announcement for the six months ended 30 June 2019 on 20 August 2019. In accordance with relevant provisions, the Company has updated relevant documents for the Proposed Issue of A Shares and submitted to the Shanghai Stock Exchange its application for resumption of the review process of the Proposed Issue of A shares (the "Application"). The Shanghai Stock Exchange has given its consent to the Application on 29 August 2019.

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the

- 1 -

Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board

Wang Hai Bo

Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

29 August 2019

* For identification purpose only

- 2 -